Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432466 | 0.91 | ALDH1A1 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL16519338 | 0.90 | DRD2 (0.40) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL7150414 | 0.87 | EGFR (0.47) | EGFRERBB2ALDH1A1MAPK1RECQL | |
| SCHEMBL1275299 | 0.86 | EGFR (0.44) | EGFRERBB2ALDH1A1MAPK1RECQL | |
| SCHEMBL15871096 | 0.85 | CYP1A2 (0.42) | EGFRERBB2ALDH1A1MAPK1RECQL | |
| SCHEMBL15065449 | 0.83 | LMNA (0.43) | EGFRERBB2MAPK1TDP1CNR2 | |
| SCHEMBL5460996 | 0.83 | LMNA (0.43) | EGFRERBB2MAPK1TDP1CNR2 | |
| SCHEMBL10340840 | 0.83 | LMNA (0.43) | EGFRERBB2MAPK1TDP1CNR2 | |
| SCHEMBL4224314 | 0.82 | EGFR (0.44) | EGFRERBB2ALDH1A1MAPK1RECQL | |
| SCHEMBL3343576 | 0.81 | L3MBTL1 (0.42) | EGFRERBB2ALDH1A1MAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089560-A1 | NOVEL NEAR-INFRARED PHOSPHOR COMPOUND AND USES THEREOF | 서울대학교산학협력단 | 2026-04-30 | — | — | WO | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-2886534-A1 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-Tech Ueno, Ltd. (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R TECH UENO LTD (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R TECH UENO LTD (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R TECH UENO LTD (JP) | 2015-06-18 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-5043332-A | Novel 11β-substituted -19-nor-steriods | ROUSSEL UCLAF (FR) | 1991-08-27 | — | — | US | disclosed |
| US-4978657-A | Antiprogesterones, antiglucocorticoids | ROUSSEL UCLAF (FR) | 1990-12-18 | — | — | US | disclosed |
| US-4634695-A | GLUCOCORTICOID INHIBITORS | ROUSSEL UCLAF (FR) | 1987-01-06 | — | — | US | disclosed |
| EP-0110434-B1 | STEROID INTERMEDIATES SUBSTITUTED AT POSITION 11, AND PROCESS FOR THEIR PREPARATION | ROUSSEL-UCLAF (FR) | 1986-10-29 | — | — | EP | disclosed |
| US-4519946-A | ANTIARTHRITIC, ANTIDIABETIC, ANTISECRETORY, AND HYPOTENSIVE AGENTS | ROUSSEL UCLAF (FR) | 1985-05-28 | — | — | US | disclosed |
| EP-0057115-B1 | STEROID DERIVATIVES SUBSTITUTED IN THE 11-BETA POSITION, PROCESS FOR THEIR PREPARATION, THEIR UTILIZATION AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1985-03-20 | — | — | EP | disclosed |
| EP-0110434-A1 | Steroid intermediates substituted at position 11, and process for their preparation | ROUSSEL-UCLAF (FR) | 1984-06-13 | — | — | EP | disclosed |
| US-4447424-A | ANTIFERTILITY, ANTIINFLAMMATORY AGENT, HORMONE INHIBITOR | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | disclosed |
| US-4386085-A | ANTIGLUCOCORTICOIDS | ROUSSELL UCLAF (FR) | 1983-05-31 | — | — | US | disclosed |
| EP-0057115-A2 | Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1982-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | DRD2 2201/4885DRD3 2398/4885DRD1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.